Sign in
Enrolling by invitationNo phase

Tracks heart transplant outcomes when donor hearts are moved in a special transport device

Studies heart transplant results when donor hearts travel in the SherpaPak device.

Key facts

Who runs it
Paragonix Technologies
Where
Boston, Cincinnati, Dallas, Durham, Fort Wayne, Gainesville, Grand Rapids, Jacksonville, Lawrence, Memphis, New York, Norfolk, Orlando, Stanford, State College, and Washington D.C., United StatesSee the 17 sitesAlso in 3 other countries, 5 sites
Trial code
Registry title
Global Utilization And Registry Database for Improved heArt preservatioN
Status
Enrolling by invitation
People taking part
4,000 people, planned
Started
14 Feb 2020
Expected to end
31 Dec 2029
Type of study
Observational, 3 groups
Treatments tested
  • SherpaPak Cardiac Transport System
Record updated
16 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people on the waiting list for a first heart transplant, including children. The donor heart is carried in the SherpaPak Cardiac Transport System.

Sex
All sexes can join.
Disease stage
People registered as candidates for a first (primary) heart transplant.
Earlier treatment
People who have already had an organ transplant cannot join.

Main reasons for not taking part

  • Donor heart does not meet the hospital's requirements for transplant
  • Safe connection to the aorta cannot be made, for example the aortic root is not long enough
  • People in prison
  • People who have had a previous organ transplant

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Donor and donor hearts matched to the prospective recipient based upon institutional medical practice
  • Registered male or female primary heart transplant candidates including pediatric candidates

Who cannot take part

  • Donor and donor hearts that do not meet institutional clinical requirements for transplantation
  • Patients who have had a previous organ transplant
  • When safe connection with the aorta cannot be made, e.g., due to lack of enough length of the aortic root
  • Patients who are incarcerated persons (prisoners)

Where in United States

Also in 3 other countries, 5 sites

  • Massachusetts General HospitalBoston, United StatesEnrolling by invitation
  • Tufts University Medical CenterBoston, United StatesEnrolling by invitation
  • Cincinnati Children's HospitalCincinnati, United StatesEnrolling by invitation
  • Baylor University Medical CenterDallas, United StatesEnrolling by invitation
  • Duke UniversityDurham, United StatesEnrolling by invitation
  • Lutheran HospitalFort Wayne, United StatesEnrolling by invitation
  • University of Florida Health Shands HospitalGainesville, United StatesEnrolling by invitation
  • Spectrum HealthGrand Rapids, United StatesEnrolling by invitation
  • Mayo ClinicJacksonville, United StatesEnrolling by invitation
  • Kansas University Medical CenterLawrence, United StatesEnrolling by invitation
  • Le Bonheur Children's HospitalMemphis, United StatesEnrolling by invitation
  • NewYork-Presbyterian / Columbia University Irving Medical CenterNew York, United StatesEnrolling by invitation
  • Sentara HealthcareNorfolk, United StatesEnrolling by invitation
  • AdventHealth OrlandoOrlando, United StatesEnrolling by invitation
  • Stanford UniversityStanford, United StatesEnrolling by invitation
  • Pennslyvania State UniversityState College, United StatesEnrolling by invitation
  • MedStar Washington HospitalWashington D.C., United StatesEnrolling by invitation

About the trial

What the trial wants to find out

The primary objective of this study is to collect real-world clinical performance data to assess the clinical outcomes of patients receiving heart transplants using donor hearts transported via the SherpaPak CTS System. These results will be compared to outcomes of retrospective patients whose hearts were transported with the previous standard method.

Read full original descriptionShow less

CONCERT DCD is a substudy designed to assess the safety and feasibility of a direct procurement method for donation after circulatory death (DCD) heart procurement (CONCERT DCD) that utilizes preservation in a SherpaPak Cardiac Transport System. This DCD Substudy will be limited to approved GUARDIAN-Heart Registry sites who have been qualified to participate. The DCD Substudy will include prospective recipient identification and documentation of informed consent.

The 3 groups in the trial

  • SherpaPak CTS Patients

    Patients whose donor heart was transported with the SherpaPak CTS

    Treatment: SherpaPak Cardiac Transport System

  • Standard Transport Patients

    Patients whose donor heart was transported with a method other than SherpaPak CTS in the past two years

  • CONCERT DCD

    Patients whose DCD heart was procured using a cold oxygenated flush with no reanimation and then transported in the SherpaPak CTS

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Global Utilization and Registry Database for Improved Heart Preservation
Plain-language title
Tracks heart transplant outcomes when donor hearts are moved in a special transport deviceGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Publications
Record updated
16 October 2026